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Analyses were conducted from both the societal and health care
system perspective. Sensitivity analyses were performed.
RESULTS: Reduction in disease outcomes, disease sequelae and
cost-of-illness by health state was observed in the time period
post-Prevnar®, across all age groups. The total cost of the vac-
cination program to the Canadian health care system (including
herd immunity effects), from a payer perspective amounted to
$74,682,790; this decreased to $46,197,274 from a societal per-
spective. The total number of illnesses avoided was 86,164. The
incremental cost-effectiveness ratio (ICER) was $28,551 and
$17,661 per additional QALY from the health system and soci-
etal perspectives, respectively. When herd immunity effects were
excluded from the analysis, the ICER increased to $166,560 and
$115,995 per QALY, respectively. Sensitivity analysis indicated
that total cost and ICER results were most sensitive to changes
in the epidemiology and cost of otitis media. However, these
changes did not considerably impact the results, indicating a
robust model. CONCLUSION: Consistent with previous ﬁnd-
ings, vaccination with Prevnar® is cost-effective. Administration
of Prevnar® results in a substantial reduction in pneumococcal
disease in vaccinated children and unvaccinated adults.
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OBJECTIVES: To investigate the cost effectiveness of gargling to
prevent upper respiratory tract infections (URI) from a societal
perspective. METHODS: The effectiveness of gargling for pre-
venting URI has been demonstrated in a randomized controlled
trial in which the participants recorded the frequency of gargling,
incidence and severity of URI and duration of daily medicine.
Costs of gargling, visiting physicians, medicine, and lost pro-
ductivity were considered. The cost of gargling was estimated as
the opportunity cost of the time required. The utility of severe
and moderate URI was also considered. Average costs and utility
during 60 days of observation in the trial were estimated as the
sum of the average daily cost and utility of the participants
remaining staying in the trial. The incremental cost effectiveness
ratio (ICER) of gargling when compared with the absence of gar-
gling was calculated, and bootstrap sampling generated an
acceptability curve. RESULTS: The estimated unit cost of gar-
gling was 49.2 yen. Assigned participants gargled 4.5 times per
day on average. The gargling group had higher costs and utility
than the group that did not gargle. The incremental cost and
effectiveness for 60 days were 4750 yen and 0.43 quality-
adjusted life days respectively. The gargling group required 8020
yen more for gargling, but saved 3270 yen by preventing URI
for 60 days. This showed that the ICER of gargling was 4.07
million yen/QALYs (34,400 US$/QALYs). The acceptability
curve showed 67.1% was less than 6 million yen/QALYs, and
88.7% less than 12 million yen/QALYs. CONCLUSION:
Although it can prevent URI, gargling is more costly than not
gargling because the cost of gargling exceeded the savings
derived from URI prevention. However, the ICER of gargling
was comparable with that of other widespread medical 
technologies.
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OBJECTIVES: Selection of the most cost-effective treatment
regimen of severe community-acquired pneumonia. METHODS:
Direct medical expenditure on courses of treatment with lev-
oﬂoxacin and ceftriaxone were evaluated during this trial. “Cost
minimization” analysis was chosen as a pharmacoeconomic
method, and a “lost opportunities” index was calculated when
using less cost-effective drugs. RESULTS: Direct medical costs in
the group of patients who received levoﬂoxacin amounted to
16,097.99 rubles, and in the group of patients who were treated
with ceftriaxone they totaled 32,573.47 rubles per patient. They
were made up of levoﬂoxacin and ceftriaxone antibacterial drug
treatment costs and the costs of patients’ hospital stay. The cost
of the drug treatment course amounted to 3,997.99 rubles for
the ﬁrst group (levoﬂoxacin) and to 19,073.47 rubles for the
second group (ceftriaxone); the cost of hospital stay amounted
to 12,100 rubles and 13,500 rubles respectively. In the break-
down of expenditure on treatment of community-acquired pneu-
monia with levoﬂoxacin, patients’ hospital stay accounted for
75% of expenses, whereas drug treatment accounted for only
25% thereof; when treating with ceftriaxone, the expenditure on
patients’ hospital stay amounted to 40% and that on drug treat-
ment—to 60%. The “lost opportunities” index equaled one and
thus indicated that when using a more cost-effective drug (lev-
oﬂoxacin) for the treatment of one patient compared to a less
cost-effective drug (ceftriaxone) it is possible to theoretically
treat an additional patient, taking into account the difference in
the costs of treatment with the drugs compared, provided the
proﬁle of antibiotic resistance is congruent with that under the
conditions of the clinical study used herein. CONCLUSION:
Antibacterial treatment of severe community-acquired pneumo-
nia with levoﬂoxacin is more cost-effective, enabling the reduc-
tion of costs by 16,475 rubles per patient compared to treatment
with ceftriaxone owing to lower expenditure on drugs.
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OBJECTIVES: Complicated skin and skin structure infections
(cSSSIs) are a common complication among hospitalized patients.
There are limited national data on the costs of cSSSIs due to
Staphylococcus aureus, a common hospital-acquired pathogen.
METHODS: This retrospective cohort study used data from the
2004 Health care Cost and Utilization Project Nationwide Inpa-
tient Sample (HCUP-NIS). Patients with S. aureus cSSSIs were
identiﬁed based on ICD-9-CM diagnosis codes and compared to
patients without skin infections. Excess mortality, length of stay
(LOS), and costs were estimated for both groups. Multivariate
models (with log transformation) were used to adjust costs for
potential confounding factors, including age, gender, mortality,
hospital region, and comorbidity. RESULTS: We identiﬁed 55,585
hospitalized patients with cSSSIs due to S. aureus. The compari-
son cohort consisted of 7,618,776 patients without skin infec-
tions. The mortality rates were similar for the S. aureus cSSSI and
comparison cohorts (3.9% and 2.0%, respectively). For com-
